We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Venetoclax combined with R‐ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy.
- Authors
Caimi, P. F.; Cashen, A.; Gallogly, M.; Winter, A.; Boughan, K.; Ghobadi, A.; Jagadeesh, D.; Cooper, B.; Mehta‐Shah, N.; Dean, R.; Metheny, L.; Pohlman, B.; Bartlett, N. L.; de Lima, M.; Kahl, B. S.; Hill, B. T.
- Abstract
B Introduction: b Patients (pts) with diffuse large B cell lymphoma (DLBCL) refractory or relapsed (r/r) after initial therapy have poor survival. The overall response (OR) rate to platinum-based second line therapy is approximately 50% with complete response (CR) rate of 30%. Venetoclax combined with R-ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy.
- Subjects
B cell lymphoma; VENETOCLAX; THERAPEUTICS
- Publication
Hematological Oncology, 2023, Vol 41, p436
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_321